New therapies are changing what is possible in generalised myasthenia gravis care, yet unequal access across Europe continues ...

Regeneron's Phase III trial investigated cemdisiran and pozelimab as both monotherapies and in combination in gMG.

The firm submitted applications based on data from the Phase III NIMBLE trial, in which cemdisiran improved patients' ability to do daily tasks.

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare and severe immune-mediated disease that affects sensory ...